Shady Swidan | Sinai University (original) (raw)
Uploads
Papers by Shady Swidan
Paclitaxel (PTX) is an anticancer drug having poor aqueous solubility and low bioavailability. Fo... more Paclitaxel (PTX) is an anticancer drug having poor aqueous solubility and low bioavailability. Formulation of PTX into Nanostructure lipid carriers (NLC) could be a potential way to enhance PTX aqueous solubility and bioavailability hence increases efficacy and decreases side effects. Eight PTX-NLC formulae were prepared using homogenization-ultrasonication technique. Characterization of the nanoparticles was done by transmission electron microscopy and by measurement of particle size, poly dispersibility index and zeta potential. Encapsulation efficiency, drug loading, and In Vitro release were measured. Particle size ranged between 172.8 ± 0.8 to 378.2 ± 1.8 nm and zeta potential between-18.6 ± 0.4 to-28.1 ± 1.2 mV. High EE and DL were obtained due to incorporation of liquid lipid and the In Vitro release showed prolonged time dependent release compared to Taxol ®. NLC-3 had the best results among the eight prepared formulae. In Vitro cytotoxicity of NLC-3 was evaluated on MCF-7 cell line and compared to pure PTX powder and Taxol ®. These findings show that NLC is a potential carrier to improve efficacy and enhance PTX delivery.
Objective: To improve the dissolution of poorly soluble Piroxicam (PRXM) by solid dispersion tech... more Objective: To improve the dissolution of poorly soluble Piroxicam (PRXM) by solid dispersion technique using water soluble carriers with or without the addition of sodium lauryl sulphate (SLS) as surfactant.
Methods and Materials: Solid dispersions of Piroxicam were prepared using different polymers such as polyethylene glycol (PEG 4000 and PEG 6000) polyvinylpyrrolidone (PVP K30 and PVP K90) without or with addition of 2% of (SLS). Solid dispersions were formulated in drug polymer ratios 1:1, 1:2, and 1:4, each ratio without or with 2% SLS using solvent evaporation method. The prepared formulae were assayed for drug content, production yield and stability properties. Dissolution profiles were done in phosphate buffer pH 7.4 and the in vitro release was evaluated according to the % released after 20, 30, 45 and 60 minutes. An accelerated stability study was done over 3 months at 40o and 60oC and with relative humidity (RH) 75%.
Results and Discussion: All of the formulated solid dispersions displayed better dissolution profiles as compared to the pure drug. Formulae containing 2% SLS displayed better in vitro release results compared to formulae prepared without SLS. The degradation of PRXM was slow, indicating the chemical stability of PRXM in all prepared formulae.
Conclusion: A formula containing PRXM to PEG 4000 in the ratio 1:1 with 2% SLS was ranked first and gave the best results among prepared formulae.
Comparative study of solid lipid nanoparticles and nanostructured lipid carriers for in vitro Paclitaxel delivery
Lipid nanoparticles are promising carriers to deliver anticancer agents of low aqueous solubility... more Lipid nanoparticles are promising carriers to deliver anticancer agents of low aqueous solubility such as Paclitaxel (PTX). The aim of this work is to improve the efficacy of Paclitaxel through formulation of Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) containing two different liquid lipids. Preparation was done using homogenization and ultrasonication technique. Nanoparticles physical characterization was done by determination of the mean particle size, zeta potential and Transmission electron microscopy (TEM). Entrapment efficiency and Differential Scanning Calorimetry (DSC) was determined. In vitro release and cytotoxicity was done and results were compared to the commercially available product Taxol ® .The mean particle diameter was between 276-314 nm, while zeta potential ranged from-20.2 and-24.9 mV. The entrapment efficiencies of prepared formulae were high(up to 87.6%) and thermal analysis revealed that the drug was in amorphous form. In vitro release through dialysis membrane showed prolonged release. In vitro cytotoxicity assay showed that IC50 of PTX-NLCs was significantly lower than that of Taxol ®. NLC containing Capryol 90 had the best results in entrapment efficiency and lowest IC50. Both SLN and NLC can be potential carriers for prolonged release and to enhance activity of PTX.
Paclitaxel (PTX) is an anticancer drug having poor aqueous solubility and low bioavailability. Fo... more Paclitaxel (PTX) is an anticancer drug having poor aqueous solubility and low bioavailability. Formulation of PTX into Nanostructure lipid carriers (NLC) could be a potential way to enhance PTX aqueous solubility and bioavailability hence increases efficacy and decreases side effects. Eight PTX-NLC formulae were prepared using homogenization-ultrasonication technique. Characterization of the nanoparticles was done by transmission electron microscopy and by measurement of particle size, poly dispersibility index and zeta potential. Encapsulation efficiency, drug loading, and In Vitro release were measured. Particle size ranged between 172.8 ± 0.8 to 378.2 ± 1.8 nm and zeta potential between-18.6 ± 0.4 to-28.1 ± 1.2 mV. High EE and DL were obtained due to incorporation of liquid lipid and the In Vitro release showed prolonged time dependent release compared to Taxol ®. NLC-3 had the best results among the eight prepared formulae. In Vitro cytotoxicity of NLC-3 was evaluated on MCF-7 cell line and compared to pure PTX powder and Taxol ®. These findings show that NLC is a potential carrier to improve efficacy and enhance PTX delivery.
Objective: To improve the dissolution of poorly soluble Piroxicam (PRXM) by solid dispersion tech... more Objective: To improve the dissolution of poorly soluble Piroxicam (PRXM) by solid dispersion technique using water soluble carriers with or without the addition of sodium lauryl sulphate (SLS) as surfactant.
Methods and Materials: Solid dispersions of Piroxicam were prepared using different polymers such as polyethylene glycol (PEG 4000 and PEG 6000) polyvinylpyrrolidone (PVP K30 and PVP K90) without or with addition of 2% of (SLS). Solid dispersions were formulated in drug polymer ratios 1:1, 1:2, and 1:4, each ratio without or with 2% SLS using solvent evaporation method. The prepared formulae were assayed for drug content, production yield and stability properties. Dissolution profiles were done in phosphate buffer pH 7.4 and the in vitro release was evaluated according to the % released after 20, 30, 45 and 60 minutes. An accelerated stability study was done over 3 months at 40o and 60oC and with relative humidity (RH) 75%.
Results and Discussion: All of the formulated solid dispersions displayed better dissolution profiles as compared to the pure drug. Formulae containing 2% SLS displayed better in vitro release results compared to formulae prepared without SLS. The degradation of PRXM was slow, indicating the chemical stability of PRXM in all prepared formulae.
Conclusion: A formula containing PRXM to PEG 4000 in the ratio 1:1 with 2% SLS was ranked first and gave the best results among prepared formulae.
Comparative study of solid lipid nanoparticles and nanostructured lipid carriers for in vitro Paclitaxel delivery
Lipid nanoparticles are promising carriers to deliver anticancer agents of low aqueous solubility... more Lipid nanoparticles are promising carriers to deliver anticancer agents of low aqueous solubility such as Paclitaxel (PTX). The aim of this work is to improve the efficacy of Paclitaxel through formulation of Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) containing two different liquid lipids. Preparation was done using homogenization and ultrasonication technique. Nanoparticles physical characterization was done by determination of the mean particle size, zeta potential and Transmission electron microscopy (TEM). Entrapment efficiency and Differential Scanning Calorimetry (DSC) was determined. In vitro release and cytotoxicity was done and results were compared to the commercially available product Taxol ® .The mean particle diameter was between 276-314 nm, while zeta potential ranged from-20.2 and-24.9 mV. The entrapment efficiencies of prepared formulae were high(up to 87.6%) and thermal analysis revealed that the drug was in amorphous form. In vitro release through dialysis membrane showed prolonged release. In vitro cytotoxicity assay showed that IC50 of PTX-NLCs was significantly lower than that of Taxol ®. NLC containing Capryol 90 had the best results in entrapment efficiency and lowest IC50. Both SLN and NLC can be potential carriers for prolonged release and to enhance activity of PTX.